A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 258-263

  Masters, Gregory A ^a   Wang, Xiaofei ^a   Hodgson, Lydia ^a   Shea, Thomas ^a   Vokes, Everett ^a   Green, Mark ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Carboplatin; Chemotherapy; High dose chemotherapy; Non small cell lung cancer; Paclitaxel; Radiotherapy; Stem cell transplant; Surgery

Indexed keywords

CARBOPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFECTION; LETHALITY; LEUKOPENIA; LUNG EDEMA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPHOCYTOPENIA; MALAISE; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RADIATION SICKNESS; SIDE EFFECT; STEM CELL MOBILIZATION; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DRUG DOSAGE CALCULATIONS; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; LUNG NEOPLASMS; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PNEUMONECTOMY; SURVIVAL ANALYSIS; THORAX;

EID: 80053628679     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.03.015     Document Type: Article

References (27)

1. Jemal A., Segal R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
3. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J Clin 1998, 48(1):6-29.
4. Martini N., Flehinger B.J., Zaman M.B., Beattie E.J. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983, 198:386-397.
5. Masters G.A., Vokes E.E., Golomb H.M. Advances in the treatment of early stage non-small cell lung cancer. Adv Oncol 1996, 12(3):16-21.
6. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small cell lung cancer: seven year follow-up of cancer and leukemia group B 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215.
7. Sause W., Scott C., Taylor S., et al. RTOG 8808/ECOG 4588 preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995, 87:198-205.
8. Roth J.A., Fossella S., Komaki R., et al. A randomized trial comparing perioperataive chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994, 86:673-689.
9. Rosell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994, 330:153-158.
10. Albain K.S., Scott C.B., Rusch V.R., et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 2003, 22:A2497.
11. Rizzieri D.A., Vredenburgh J.J., Jones R., et al. Prognostic and predictive factors for patients with metastatic breast cancer undergoing appressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999, 17:3064-3074.
12. Iwasaki Y., Nagata K., Nakanishi M., et al. Chest 2005, 128(4):2268-2273.
13. De Vries E.G., de Graaf H., Boonstra A., et al. High-dose chemotherapy with stem cell reinfusion and growth factor support for solid tumors. Stem Cells 1995, 13(6):597-606.
14. Nieboer P., de Vries E.G., Mulder N.H., van der Graaf W.T. Relevance of high dose chemotherapy in solid tumors. Cancer Treat Rev 2005, 31(3):210-225.
15. Shea T., et al. Multiple cycles of high dose paclitaxel plus escalating doses of carboplatin with G-CSF and peripheral blood stem cell support. Proc ASCO 1555, 478:1995.
16. Evans B., Raju K., Calvert A., et al. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep 1983, 67:997.
17. Rowinsky E.K., Cazenave L.A., Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J NCI 1990, 82:1247-1259.
18. Kelly K., Pan Z., Murphy J., Huffman D.H., Bunn P. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 1997, 3(7):1117-1123.
19. Johnson D.H., Paul D.M., Hande K.R., et al. Carboplatin and paclitaxel in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1996, 14:2054.
20. Langer C.J., Leighton J., Comis R., et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 1995, 13:1860-1870.
21. Cockcroft D.W., Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
22. Calvert A.H., Newell D.R., Grumbell L.A., et al. Carboplatin dosage. Prospective evaluation of a single formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10(March (1)):1-10.
24. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
25. Savarese D.M.F., Hsieh C., Stewart F.M. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997, 15:2981-2995.
26. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995, 13:1880-1892.
27. Sauvaget J., Rebischung J.-L., Vannetzel J.-M. Phase III study of neo-adjuvant MVP versus MVP plus chemo-radiotherapy in stage III NSCLC. Proc Am Soc Clin Oncol 2000, 19:A1935.